Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(3)
•••
Comment by themagicboxon Feb 24, 2020 2:53pm
110 Views
Post# 30727312

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Delays & dilution

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Delays & dilutionLOL sorry buddy. Swing and a miss....I'm saying my info based on multiple factors. Your imagination can only fathom "he sold his shares".... clinics have spoken....I sold a major chuck on 68 for sure *wink* I can again way more now, but it will drop more


For full disclosure, I'm playing the daily,  like others on this board...enjoy the peasant method of investing....meanwhile the shorters will f**k this stock hard....got a few buddies in the biz haha....enjoy watching it fall

Mickey2 wrote: qwerty22, dont waste too much of your time with themagicbox.  Look back on the post i made about themagicbox...themagicbox was a bull up to Feb 3rd 2020...Then on Feb 4th, he flipped. Easy to see.  He just wants back in after selling all his shares.
  


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities